A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
PHASE3Not yet recruitingINTERVENTIONAL
Enrollment
35
Participants
Timeline
Start Date
October 25, 2025
Primary Completion Date
January 25, 2031
Study Completion Date
January 25, 2031
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG
Pozelimab
Administered per the protocol
DRUG
Cemdisiran
Administered per the protocol
All Listed Sponsors
lead
Regeneron Pharmaceuticals
INDUSTRY
NCT07154745 - A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently | Biotech Hunter | Biotech Hunter